ViewRay Inc. – Nasdaq: VRAY
ViewRay Inc. shares are up over 25% on news that the German Research Foundation (DFG), a federal institution supporting research in Germany, has purchased a MRIdian Linac for installation and patient treatments at the University Clinic Heidelberg as part of its initiative for MRI-based radiation therapy. The shares are traded on the Nasdaq under ticker VRAY and are experiencing heavy trading volume this morning.
ViewRay, Inc. designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients. In the United States, ViewRay has submitted a 510(k) application for the MRIdian Linac, the company’s MR Linac technology. Therefore, the MRIdian Linac is not available for sale or distribution in the United States except for non-clinical research use.
ViewRay Inc. has experienced increasing sales figures. In 2012 the company reported sales of $1.9 million and in 2015 ViewRay reported sales of $10.4 million. However, EPS for shareholders of VRAY have experienced increasing negative EPS. In 2012 VRAY had an EPS loss of $0.66 and in 2015 VRAY had an EPS loss of $1.18. Two firms follow ViewRay and both rate VRAY shares as a “Strong Buy” with a $6 consensus price target.
I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.
|Last Price a/o 12:22 PM EST||$ 3.90|
|Market Cap||$136.9 million|
|Shares Outstanding||43.61 million|
|Share Float||37.76 million|
|Short Interest Ratio||14.11|